|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300070018 |
|
最近更新日期: Date of Last Refreshed on: |
2023-03-31 10:31:25 |
|
注册时间: Date of Registration: |
2023-03-31 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
妇科恶性肿瘤术后患者下肢淋巴水肿预防方案构建及多中心临床应用研究 |
|
Public title: |
Construction of a prevention plan for lower limb lymphedema in patients with gynecological malignant tumors after surgery and a multicenter clinical application study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
妇科恶性肿瘤术后患者下肢淋巴水肿预防方案构建及多中心临床应用研究 |
|
Scientific title: |
Construction of a prevention plan for lower limb lymphedema in patients with gynecological malignant tumors after surgery and a multicenter clinical application study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
伊焕英 |
研究负责人: |
伊焕英 |
|
Applicant: |
Huanying Yi |
Study leader: |
Huanying Yi |
|
申请注册联系人电话: Applicant telephone: |
15248936373 |
研究负责人电话:
Study leader's |
15248936373 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
m15248936373@163.com |
研究负责人电子邮件: Study leader's E-mail: |
m15248936373@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
海南省海口市龙华区城西学院路3号海南医学院 |
研究负责人通讯地址: |
海南省海口市龙华区城西学院路3号海南医学院 |
|
Applicant address: |
Hainan Medical University, 3 Chengxi Xueyuan Road, Longhua District, Haikou City, Hainan Province |
Study leader's address: |
Hainan Medical University, 3 Chengxi Xueyuan Road, Longhua District, Haikou City, Hainan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
海南医学院 |
||
|
Applicant's institution: |
Hainan Medical University |
||
|
研究负责人所在单位: |
海南医学院 |
||
|
Affiliation of the Leader: |
Hainan Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
HYLL-2022-201 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
海南医学院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Hainan Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-04-11 00:00:00 | ||
|
伦理委员会联系人: |
吴英 |
||
|
Contact Name of the ethic committee: |
Ying Wu |
||
|
伦理委员会联系地址: |
海南省海口市龙华区城西学院路3号海南医学院 |
||
|
Contact Address of the ethic committee: |
Hainan Medical University, 3 Chengxi Xueyuan Road, Longhua District, Haikou City, Hainan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
海南医学院 |
||||||||||||||||||||||
|
Primary sponsor: |
Hainan Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
海南省海口市龙华区城西学院路3号海南医学院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Hainan Medical University, 3 Chengxi Xueyuan Road, Longhua District, Haikou City, Hainan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
海南省自然科学基金基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Supported by Hainan Provincial Natural Science Foundation of China |
||||||||||||||||||||||
|
研究疾病: |
妇科恶性肿瘤 |
||||||||||||||||||||||
|
Target disease: |
Gynecology malignant tumor |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
基于循证形成妇科恶性肿瘤术后患者下肢淋巴水肿证据总结,并基于渥太华研究应用模式构建下肢淋巴水肿预防方案,旨在帮助患者预防和延缓下肢淋巴水肿的发生和进展,为妇科恶性肿瘤术后患者开展科学的、合理的预防措施提供理论依据。通过将预防下肢淋巴水肿干预方案在多中心进行临床应用,旨在验证该方案临床实践的有效性和推广性,明确可实施的妇科恶性肿瘤术后患者下肢淋巴水肿的预防方案。 |
||||||||||||||||||||||
|
Objectives of Study: |
Based on the evidence-based summary of the evidence of lower limb lymphedema in patients after gynecological malignant tumor surgery, and based on the Ottawa research and application model, the lower limb lymphedema prevention program is constructed, aiming at helping patients prevent and delay the occurrence and progression of lower limb lymphedema, and providing theoretical basis for carrying out scientific and reasonable preventive measures for patients after gynecological malignant tumor surgery. Through the clinical application of the intervention program for the prevention of lower limb lymphedema in the multi-center, the purpose is to verify the effectiveness and popularization of the clinical practice of the program, and to identify the feasible prevention program for lower limb lymphedema in patients with gynecological malignant tumor after surgery. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
组织病理诊断为宫颈癌、子宫内膜癌、外阴癌、卵巢癌;接受盆腔或腹股沟或腹主动脉淋巴结切除术的手术治疗;年龄≥18岁;自愿参与。 |
||||||||||||||||||||||
|
Inclusion criteria |
Histopathological diagnosis of cervical cancer, endometrial cancer, vulvar cancer, ovarian cancer; Surgical treatment with pelvic or inguinal or aortic lymphadenectomy; ≥18 years of age; Volunteer. |
||||||||||||||||||||||
|
排除标准: |
发生下肢静脉血栓、慢性静脉功能不全、心肝肾等重要脏器功能衰竭、低蛋白血症;合并其他癌症或者在研究期间出现癌症复发或转移的患者;精神上无法完成康复训练;在研究期间因其余术后并发症需要改变治疗策略的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Lower limb venous thrombosis, chronic venous insufficiency, heart, liver, kidney and other important organ failure, hypoproteinemia; Patients with other cancers or cancer recurrence or metastasis during the study period; Mentally unable to complete rehabilitation training; Patients who required a change in treatment strategy due to other postoperative complications during the study period. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-03-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-04-01 00:00:00 至 To 2026-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由研究者采用投硬币的方法,硬币正面进入实验组,反面进入对照组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The researchers use the coin method, the side of the coin into the experimental group, the reverse side into the control group. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2026年12月,Resman数据库公开数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
In December 2026, Resman database public data |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |